Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and Its Death Receptor (DR5) in Peyronie's Disease. A Biomolecular Study of Apoptosis Activation

Journal of Sexual Medicine

Volumn 8, Issue 1, 2011, Pages 109-115

  Loreto, Carla ^a   Barbagli, Guido ^b   Djinovic, Rados ^c   Vespasiani, Giuseppe ^d   Carnazza, Maria Luisa ^a   Miano, Roberto ^d   Musumeci, Giuseppe ^a   Sansalone, Salvatore ^d  

^a UNIVERSITY OF CATANIA   (Italy)

^b Centre for Reconstructive Urethral Surgery   (Italy)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Apoptosis; DR5; Peyronie's Disease; Peyronie's Plaque Healing; TRAIL

Indexed keywords

DEATH RECEPTOR 5; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR MECHANICS; PATHOPHYSIOLOGY; PEYRONIE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUNICA ALBUGINEA; WESTERN BLOTTING;

EID: 78650800116     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.02003.x     Document Type: Article

References (47)

1. Jordan GH, Schlossberg SM, Devine CJ. Surgery of the penis and urethra. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, eds. Campbell's urology. 7th edition. Philadelphia: WB Saunders; 1998:3376-94.
2. Noss MB, Day NS, Christ GJ, Melman A. The genetics and immunology of Peyronie's disease. Int J Impot Res 2000;4:S127-390.
3. Hellstrom WJ, Bivalacqua TJ. Peyronie's disease: Etiology, medical, and surgical therapy. J Androl 2000;21:347-54.
4. Gholami SS, Lue TF. Peyronie's disease. Urol Clin North Am 2001;28:377-90.
5. Rhoden EL, Teloken C, Ting HY, Lucas ML, Teodósio da Ros C, Ary Vargas Souto C. Prevalence of Peyronie's disease in men over 50 years old. J Urol 2001;165:200.
6. McVary KT. Peyronie's disease. Paper presented at the annual meeting of the American Urological Association, Anaheim, CA, 2001.
7. Gonzalez-Cadavid NF, Magee TR, Ferrini M, Qian A, Vernet D, Rajfer J. Gene expression in Peyronie's disease. Int J Impot Res 2002;14:361-74.
8. Davis CJ. The microscopic pathology of Peyronie's disease. J Urol 1997;157:282-4.
9. Devine CJ, Somers KD, Jordan SG, Schlossberg SM. Proposal: Trauma as the cause of the Peyronie's lesion. J Urol 1997;157:285-90.
10. Jarow JP, Lowe FC. Penile trauma: An etiologic factor in Peyronie's disease and erectile dysfunction. J Urol 1997;158:1388-90.
11. Ehrlich HP. Scar contracture: Cellular and connective tissue aspects in Peyronie's disease. J Urol 1997;157:316-9.
12. Hellstrom WJG, Cockerham YR. Intralesional injection therapy for Peyronie's disease. J Sex Med 2009;6:1811-4.
13. Huppertz B, Kaufmann HGFP. The apoptosis cascade-morphological and immunohistochemical methods for its visualization. Anat Embryol 1999;200:1-18.
14. Tschoeke SK, Hellmuth M, Hostmann A, Robinson Y, Ertel W, Oberholzer A, Heyde CE. Apoptosis of human intervertebral discs after trauma compares to degenerated discs involving both receptor-mediated and mitochondrial-dependent pathways. J Orthop Res 2008;26:999-1006.
15. Ferri KF, Kroemer G. Organelle-specific initiation of cell death pathway. Nat Cell Biol 2001;3:255-63.
16. Egydio PH, Sansalone S. Peyronie's reconstruction for maximum length and girth gain: Geometrical principles. Adv Urol 2008;2008:205739 (Epub 2008).
17. Nesbit RM. Congenital curvature of the phallus: Report of three cases with description of corrective operation. J Urol 1965;93:230-2.
18. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
19. Somers KD, Dawson DM. Fibrin deposition in Peyronie's disease plaque. J Urol 1997;157:306-16.
20. Shindel AW, Lin G, Ning H, Banie L, Huang YC, Lin G, Lin CS, Lue FL. Pentoxifylline attenuates transforming growth factor-ß1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: Impact on extracellular matrix. J Sex Med 2010;7:1787-97.
21. Young LX, Bella AJ, O'Gorman DB, Gan BS, Lim KB, Brock GB. Protein biomarker analysis of primary Peyronie's disease cells. J Sex Med 2010;7:99-106.
22. El-Sakka AL, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF. An animal model of Peyronie's-like condition associated with an increase of trasforming growth factor beta mRNA and protein expression. J Urol 1997;158:2284-90.
23. El-Sakka AL, Hassan MU, Nunes L, Bhatnagar RS, Yen TS, Lue TF. Histological and ultrastructural alterations in an animal model of Peyronie's disease. Br J Urol 1998;81:445-52.
24. Ferrini MG, Vernet D, Magee TR, Shahed A, Qian A, Rajfer J, Gonzalez-Cadavid NF. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 2002;6:283-94.
25. Ferrini MG, Magee TR, Vernet D, Rajfer J, Gonzalez-Cadavid NF. Aging-related expression of inducible nitric oxide synthase and markers of tissue damage in rat penis. Biol Reprod 2001;64:974-82.
26. Vernet D, Ferrini MG, Valente EG, Magee TR, Bou-Gharios G, Rajfer J, Gonzalez-Cadavid NF. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model. Nitric Oxide 2002;7:262-76.
27. Gonzalez-Cadavid NF, Rajfer J. Experimental models of Peyronie's disease. Implication for new therapies. J Sex Med 2009;6:303-13.
28. Bivalacqua TJ, Diner EK, Novak TE, Vohra Y, Sikka SC, Champion HC, Kadowitz PJ, Hellstrom WJ. A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol 2000;163:1992-8.
29. Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: A new animal model of Peyronie's disease. BJU Int 2003;91:830-8.
30. Teramoto T, Kiss A, Thorgeirsson SS. Induction of p53 and Bax during TGF-beta 1 initiated apoptosis in rat liver epithelial cells. Biochem Biophys Res Commun 1998;251:56-60.
31. Sulkowski S, Wincewicz A, Sulkowska M, Koda M. Transforming growth factor-beta1 and regulators of apoptosis. Ann N Y Acad Sci 2009;1171:116-23.
32. Mulsow JJ, Watson RW, Fitzpatrick JM, O'Connell PR. Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. Ann Surg 2005;242:880-7.
33. McKaig BC, Hughes K, Tighe PJ, Mahida YR. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol 2002;282:C172-82.
34. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003;22:8628-33.
35. Hasel C, Durr S, Rau B, Strater J, Schmid RM, Walczak H, Bachem MG, Moller P. In chronic pancreatitis, widespread emergence of TRAIL receptors in epithelia coincides with neoexpression of TRAIL by pancreatic stellate cells of early fibrotic areas. Lab Invest 2003;83:825-36.
36. Robertson NM, Rosemiller M, Lindemeyer RG, Steplewski A, Zangrilli JG, Litwack G. TRAIL in the airways. Vitam Horm 2004;67:149-67.
37. Sanlioglu AD, Korcum AF, Pesterelli E, Erdogan G, Karaveli S, Savas B, Griffith TS, Sanlioglu VMD. Trail death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat Oncol Biol Phys 2007;69:716-23.
38. Leonardi R, Almeida LE, Trevilatto PC, Loreto C. Occurrence and regional distribution of TRAIL and DR5 on temporomandibular joint discs: Comparison of disc derangement with and without reduction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109:244-51.
39. Loreto C, Musumeci G, Leonardi R. Chondrocyte-like apoptosis in temporomandibular joint disc internal derangement as a repair-limiting mechanism. An in vivo study. Histol Histopathol 2009;24:293-8.
40. Cui M, Wang L, Liang X, Ma X, Liu Y, Yang M, Liu K, Wei X, Zhou Z, Chen YH, Sun W. Blocking TRAIL-DR5 signaling with soluble DR5 reduces delayed neuronal damage after transient global cerebral ischemia. Neurobiol Dis 2010;34:138-47.
41. Pardo A, Barrios R, Maldonado V, Meléndez J, Ruiz V, Segura L, Sznajder JI, Selman M. Gelatinases A and B are upregulated in lung rats by subacute hyperoxia. Pathogenetic implications. Am J Pathol 1998;153:833-44.
42. Setton LA, Chen J. Mechanobiology of the intervertebral disc and relevance to disc degeneration. J Bone Joint Surg Am 2006;88:52-7.
43. Wang J, Zohar R, McCulloch CA. Multiple roles of alpha smooth muscle actin in mechanotransduction. Exp Cell Res 2006;312:205-14.
44. Gelbard M. Myofibroblasts and mechanotransduction: Do forces in the tunica albuginea contribute to Peyronie's disease? J Sex Med 2008;5:2973-6.
45. Chen B, Ma B, Yang S, Xing X, Gu R, Hu Y. DR5 and DcR2 are expressed in human lumbar intervertebral discs. Spine 2009;34:E677-81.
46. Gruber HE, Hanley EN. Analysis of aging and degeneration of the human intervertebral disc: Comparison of surgical specimens with normal control. Spine 1998;23:751-7.
47. Piao SP, Choi MJ, Tumurbaatar M, Kim WJ, Jin HR, Shin SH, Tuvshintur B, Yin GN, Song JS, Kwon MH, Lee SJ, Han JY, Kim SJ, Ryu JK, Suh JK. Trasforming growth factor (TGF)-ß type I receptor kinase (ALK5) inhibitor alleviates profibrotic TGF-ß1 responses in fibroblasts derived from Peyronie's plaque. J Sex Med 2010; Mar 11 [Epub ahead of print] doi: 10.1111/j.1743-6109.2010.01753.x.